Source abstract
Abstract
Nanoparticle drug-delivery systems (NP DDS) have proven to be tremendously impactful for delivering therapeutic agents in cancer treatments, vaccinations, gene therapy, and diagnostics, and enabled agents such as RNA therapeutics. However, the exposure of NP DDS to biological milieus leads to the rapid adsorption of proteins and other molecules, forming a proteinaceous corona that obscures NP surface characteristics and controls the biological interactions of the NP DDS. Surface modifications, including poly(ethylene glycol) (PEG) and synthetic zwitterionic polymers, reduce protein adsorption yet lack monomer-scale tunability, have off-target immunological effects, and suffer from targeting-limited steric hindrance, altogether motivating the development of alternative approaches. Peptides can uniquely form many zwitterions and have shown promise in reducing and controlling the NP protein corona as a function of the peptide sequence. However, the impact of zwitterionic peptides (ZIPs) on the drug-delivery properties of polymeric NPs has not been explored. In this work, diverse ZIPs computationally predicted to reduce protein adsorption by assessing peptide–peptide β-strand interaction energies were conjugated to pH-responsive cationic NPs. The resulting ZIP-NP conjugates exhibited up to 88% reduced protein adsorption and a range of siRNA-mediated gene knockdown that correlates with interaction energies. These data suggest that the peptide–peptide interaction energy is a promising design parameter for ZIPs for further model development. ZIP-NP also exhibited sequence-dependent variations in cellular uptake and circulation half-life, indicating that ZIP-NPs are suitable for tuning and improving NP drug-delivery characteristics.
Source: openalex_inverted_index · Quality: baseline
Affiliations
Department of Biomedical Engineering, University of Rochester, Rochester, New York 14627, United States
Center for Musculoskeletal Research, University of Rochester, Rochester, New York 14642, United States
Department of Chemical Engineering, University of Rochester, Rochester, New York 14611, United States
Materials Science Program, University of Rochester, Rochester, New York 14627, United States
Department of Bioengineering, Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, Oregon 97403, United States
Funding
National Institute of Dental and Craniofacial Research · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Division of Chemical, Bioengineering, Environmental, and Transport Systems · Division of Materials Research